Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Total Non-Current Liabilities of $4.0 billion for Q1 2026, down 2.95% on a QoQ basis from $4.2 billion in Q4 2025, and down 1.12% year-over-year from $4.1 billion in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $4.0 billion for Q1 2026.
- Quarterly Total Non-Current Liabilities fell 1.12% year-over-year to $4.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 billion (down 1.12% YoY) and the FY2025 annual result came in at $4.2 billion, up 13.12% from the prior year.
- Total Non-Current Liabilities was $4.0 billion for Q1 2026 at Alnylam Pharmaceuticals, down from $4.2 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $4.6 billion in Q3 2025 and bottomed at $2.9 billion in Q1 2022.
- A 5-year average of $3.7 billion and a median of $3.7 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities increased 29.54% — and 2024, when it decreased 1.5%.
- Alnylam Pharmaceuticals' Total Non-Current Liabilities stood at $3.5 billion in 2022, then climbed by 7.16% to $3.7 billion in 2023, then decreased by 1.5% to $3.7 billion in 2024, then increased by 13.12% to $4.2 billion in 2025, then dropped by 2.95% to $4.0 billion in 2026.
- Business Quant data shows ALNY's Total Non-Current Liabilities at $4.0 billion in Q1 2026, $4.2 billion in Q4 2025, and $4.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 4.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.05 Bn |
| Dec 31, 2025 | 4.17 Bn |
| Sep 30, 2025 | 4.61 Bn |
| Jun 30, 2025 | 4.30 Bn |
| Mar 31, 2025 | 4.09 Bn |
| Dec 31, 2024 | 3.69 Bn |
| Sep 30, 2024 | 3.82 Bn |
| Jun 30, 2024 | 3.66 Bn |
| Mar 31, 2024 | 3.72 Bn |
| Dec 31, 2023 | 3.74 Bn |
| Sep 30, 2023 | 3.72 Bn |
| Jun 30, 2023 | 3.55 Bn |
| Mar 31, 2023 | 3.43 Bn |
| Dec 31, 2022 | 3.49 Bn |
| Sep 30, 2022 | 3.42 Bn |
| Jun 30, 2022 | 3.00 Bn |
| Mar 31, 2022 | 2.91 Bn |
| Dec 31, 2021 | 2.96 Bn |
| Sep 30, 2021 | 2.64 Bn |
| Jun 30, 2021 | 2.58 Bn |